DOI: 10.1055/s-00000088

TumorDiagnostik & Therapie

References

Röllig C, Serve H, Hüttmann A. et al.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial.

Lancet Oncol 2015;
16: 1691-1699 . doi:10.1016/S1470-2045(15)00362-9

Download Bibliographical Data

Access:
Access:
Access: